Palatin Reinitiates Enrollment Of Phase 2 Study With PL9643 To Treat Dry Eye Disease

Biopharmaceutical company Palatin Technologies, Inc. (PTN) announced Wednesday the reinitiation of enrollment of its Phase 2 clinical study with PL9643 for the treatment of dry eye disease (DED). The company had paused patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic.

from RTT - Biotech https://ift.tt/31VhOnv
via IFTTT